1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Apical Sodium-Dependent Bile Acid Transporter

Apical Sodium-Dependent Bile Acid Transporter

ASBT; Ileal Bile Acid Transporter; IBAT; SLC10A2

Apical sodium-dependent bile acid transporter (ASBT, also known as IBAT-ileal bile acid transporter, SLC10A2) an ileal Na+-dependent transporter, actively reabsorbs bile acids (BAs) from the gut lumen. Bile acids are synthesized in the liver, stored in the gallbladder, and secreted into the duodenum at meals. ASBT is found on the brush border/apical membrane of ileal enterocytes, as well as the apical surface of renal tubules and cholangiocytes. Conjugated bile acids are actively transported by IBAT from the lumen/ apical side into the interior of the enterocyte and exported via the basolateral membrane organic solute transporter α/β heterodimer (OSTα/β; encoded by SLC51A/B) into the portal circulation, which allows for return of bile acids back to the liver. This process is a critical step in the enterohepatic circulation (EHC) of BAs and plays important roles in the homeostasis of BAs in the body. Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. In addition, ASBT is also a popular delivery target for developing prodrugs, due to its intestinal localization, high expression and high uptake capacity.

Apical Sodium-Dependent Bile Acid Transporter Related Products (12):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109120
    Odevixibat
    Inhibitor 99.92%
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
    Odevixibat
  • HY-16643
    Linerixibat
    99.98%
    Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment.
    Linerixibat
  • HY-15790
    Elobixibat
    Inhibitor 99.88%
    Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
    Elobixibat
  • HY-16747
    Maralixibat chloride
    Inhibitor 99.08%
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.
    Maralixibat chloride
  • HY-129982
    SC-435
    98.73%
    SC-435 is an apical sodium-dependent Bile acid (BA) transporter inhibitor. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations.
    SC-435
  • HY-109120S
    Odevixibat-d5
    Inhibitor
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
    Odevixibat-d<sub>5</sub>
  • HY-109120S1
    Odevixibat-13C6
    Inhibitor
    Odevixibat-13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
    Odevixibat-<sup>13</sup>C<sub>6</sub>
  • HY-15790A
    Elobixibat hydrate
    Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research.
    Elobixibat hydrate
  • HY-101190
    Volixibat
    Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH).
    Volixibat
  • HY-148795
    Ritivixibat
    Inhibitor
    Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Ritivixibat
  • HY-19298
    S-8921
    S-8921 is an ileal Na+/bile acid cotransporter (IBAT) inhibitor.
    S-8921
  • HY-19264
    264W94
    264W94 is a potent ileal bile acid transporter (IBAT) inhibitor and a new cholesterol lowering agent. 264W94 has CYP7A1 induction, and antilipemic action.
    264W94